XTL to Present at Oppenheimer's Pain Management Conference
05 March 2007 - 8:30PM
PR Newswire (US)
XTL Biopharmaceuticals to Present at Oppenheimer's "Positioning
Investors for the Next Wave in Pain Management" Conference NEW
YORK, March 5 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced today that Ron Bentsur,
the Company's Chief Executive Officer, is scheduled to present
tomorrow at Oppenheimer's "Positioning Investors for the Next Wave
in Pain Management" Conference. Mr. Bentsur will present an
overview of Bicifadine, the Company's recently in-licensed
late-stage clinical compound for the treatment of neuropathic pain,
in a presentation titled: "Bicifadine - A New Idea for Neuropathic
Pain." Mr. Bentsur's presentation will take place on Tuesday, March
6, 2007, at 2:25pm-2:40pm Eastern Standard Time followed by a
question and answer session from 2:55pm-3:15pm., at the Flatotel
Hotel in New York City. A live audio webcast of Mr. Bentsur's
presentation will be available at:
http://www.wsw.com/webcast/opp/xtl.l/. An archived version of the
webcast will be available following the conclusion of the live
presentation. ABOUT XTL BIOPHARMACEUTICALS LTD. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition,
development and commercialization of therapeutics for the treatment
of neuropathic pain and hepatitis C. XTL is developing Bicifadine,
a serotonin and norepinephrine reuptake inhibitor, for the
treatment of neuropathic pain. In addition, XTL is developing
XTL-2125 - a small molecule, non-nucleoside inhibitor of the
hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1
clinical trial in patients with chronic hepatitis C. XTL is also
developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus - presently in Phase 1 clinical
trials in patients with chronic hepatitis C. XTL's hepatitis C
pipeline also includes several families of pre-clinical hepatitis C
small molecule inhibitors. XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional
drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact:
Ron Bentsur, Chief Executive Officer Tel: +1-(212)-531-5960
DATASOURCE: XTL Biopharmaceuticals Ltd CONTACT: Contact: Ron
Bentsur, Chief Executive Officer, Tel: +1-(212)-531-5960
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024